

Zhenlei Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1815740/publications.pdf>

Version: 2024-02-01

15
papers

69
citations

1684188

5
h-index

1588992

8
g-index

15
all docs

15
docs citations

15
times ranked

68
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a rapid and sensitive UPLC-MS/MS method for quantification of kukoamine B in human plasma: Application to a clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 132, 1-6.	2.8	14
2	First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3053-3060.	3.8	13
3	Effect of Food on the Pharmacokinetic and Pharmacodynamic Profiles of Hetrombopag in Healthy Volunteers. <i>Clinical Therapeutics</i> , 2020, 42, 2280-2288.	2.5	10
4	Pharmacokinetics of Ginsenoside Rh2, the Major Anticancer Ingredient of Ginsenoside H Dripping Pills, in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 669-674.	1.6	8
5	Development and validation of a UPLC-MS/MS method for simultaneous determination of fotaliptin and its two major metabolites in human plasma and urine. <i>Bioanalysis</i> , 2017, 9, 381-393.	1.5	7
6	Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1667-1678.	3.6	3
7	Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects. <i>Clinical Drug Investigation</i> , 0, , .	2.2	3
8	Ultra performance liquid chromatography tandem mass spectrometry assay for determination of kukoamine B in human blood and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1031, 8-14.	2.3	2
9	Pharmacokinetics and safety of tiotropium+olodaterol 5 μ g/5 μ g fixed-dose combination in Chinese patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 63, 101944.	2.6	2
10	First-in-human safety, tolerability, and pharmacokinetics of SY-007, a prolonged action neuroprotective drug for ischemic stroke, in healthy Chinese subjects. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 170, 106104.	4.0	2
11	A UPLC-MS/MS method for quantification of 5 α -androst-3 β ,5,6 β -triol in human plasma: development, validation and its application in clinical pharmacokinetic study. <i>Bioanalysis</i> , 2017, 9, 873-885.	1.5	1
12	An ultra HPLC-MS/MS method for quantification of hypidone hydrochloride (YL-0919) and application to a pharmacokinetic study. <i>Bioanalysis</i> , 2019, 11, 1243-1254.	1.5	1
13	Development and validation of a UPLC-MS/MS method for quantification of C-005, a novel third-generation EGFR TKI, and its major metabolite in plasma: Application to its first-in-patient study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1162, 122475.	2.3	1
14	LC-MS/MS assay for the determination of tat-K13, a novel interfering peptide for the treatment of ischemic stroke, in human plasma and its application to a pharmacokinetics study. <i>Biomedical Chromatography</i> , 2021, 35, e5095.	1.7	1
15	Impact of target-mediated drug disposition on hetrombopag pharmacokinetics and pharmacodynamics in Chinese healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	2.4	1